Navigation Links
Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
Date:10/22/2008

Of 51 patients in the FOLFOX arm, 23 achieved disease control, including five with partial responses (or 13 percent of evaluable patients). Nine patients in the FOLFOX arm were either not evaluable or too early to evaluate.

"These interim, proof-of-concept Phase 2 colorectal cancer study results are encouraging and continue to suggest the potential of picoplatin as a neuropathy-sparing first-line therapy for metastatic colorectal cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "We are committed to developing picoplatin as a preferred platinum therapy for patients with metastatic colorectal cancer who cannot tolerate the toxicity profile of currently marketed platinums, and we are optimistic that the additional data from this trial support that strategy. We are continuing to observe the study population in order to obtain progression-free and overall survival data, potentially supporting the future development of picoplatin."

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in CRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evalu
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
(Date:5/17/2013)... 17, 2013 New interactive ... innovative thought leaders of the medical device industry ... conference and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These ... industry professionals practical presentations and implementable solutions on ...
(Date:5/17/2013)... FL (PRWEB) May 17, 2013 Men’s skin ... La-roche Posay ) and has been known to ... Although some men may be far from puberty, other acne ... clogging pores, causing breakouts, and threatening skin with unsightly acne ... advice from Men’s Health on how to reduce ...
(Date:5/17/2013)... Darrington, WA (PRWEB) May 17, 2013 Tooth ... 5th graders showing active signs of the disease. The World ... children and nearly 100% of adults have cavities. What are ... Research is showing a strong connection between the oral ... why is this disease so rampant, yet it is also ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Research Group, Inc.,released its third annual TreatmentTrends(TM): The ... into the management of,Rheumatoid Arthritis (RA), Psoriatic Arthritis ... on responses to an online survey,completed by 100 ... the study, the majority of Rheumatologists reported an,increase ...
... Ill., Sept. 17 Baxter,International (NYSE: BAX ), ... quarter 2008 financial results on Thursday, October 16, 2008, ... access the call, please,dial 866- 238-0637 (domestic) or 703-639-1156 ... prior to the start of the call for the,operator ...
... innovator relocates to Mass. based upon Gov. Deval ... Patrick,s Life Sciences Initiative -, ... Technologies, -- WHAT: Dedication of its new HQ/manufacturing facility, ... 5:00 p.m. EDT, -- WHERE: 44 Hartwell Avenue, Lexington, ...
Cached Biology Technology:Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis? 2Baxter International Third Quarter 2008 Financial Results Conference Call 2RainDance Technologies to Dedicate New Headquarters, Manufacturing Facility in Lexington 2
(Date:5/16/2013)... S.C. , May 16, 2013 ... in combination with a custom thin film transistor ... highest forensic quality roll image in the smallest ... today. Sherlock, an Appendix F Mobile ID FAP ... a 95% reduction in size and weight when ...
(Date:5/16/2013)... at sites outside the bone marrow in the ... in Munich now show that a specific type of ... cells. , Balanced hematopoiesis is essential for the function ... place mainly in the liver and the spleen. Later ... this tissue normally serves as the sole source of ...
(Date:5/16/2013)... Cameroon and the manager of San Diego Zoo Global,s ... Whitley award. The Whitley award is an international ... it celebrates the extraordinary achievements of some of the ... was selected for the award due to his efforts ... its wildlife inhabitants., HRH The Princess Royal, the charity,s ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... been identified in the brain which, if used artificially, may ... and Alzheimer,s. By looking at what happens in ... speculation over whether a key molecule, ,KCC2, causes brain cell ... today (16th May 2011) in The Journal of Physiology ...
... Research Institute have identified a class of compounds that could ... In a new study, published online in Nature ... the new compounds powerfully and selectively block the activity of ... hydrolases." Previously discovered serine hydrolase-blocking compounds have been turned into ...
... of having pet animals in their houses have the gut ... recognize our faces, our voices and our smell. One way ... , Actually, this is not just a gut feeling. Numerous ... chickens, pigeons, sheep, dogs, llamas, penguins, seals, rabbits, horses, lizards ...
Cached Biology News:New understanding of brain chemistry could prevent brain damage after injury 2Scientists find new class of compounds with great potential for research and drug development 2Scientists find new class of compounds with great potential for research and drug development 3I know you, bad guy! 2I know you, bad guy! 3
... Dithiothreitol DTT ... UNDER INERT GAS. Purity: ... Heavy metals: Absorbance: ... dithiothreitol:≤0.5%. Soluble in EtOH or ...
... Faster speeds, highest precision, more user-friendliness ... concept: this is the definition of the ... years nucleic acid research has been developing ... required of PCR Systems. To keep ...
... designed for easy transformation of the budding ... successful transformation simply by mixing a plasmid ... yeast cells. No complicated steps, such as ... kit is particularly well suited for high-throughput ...
... LabX light balance makes your life easier. It offers ... and management for one balance. *Instruments supported: ... AX, MX, UMX, AG, XS, XP, PR, SR, PG-S, ... *Job management: User ...
Biology Products: